Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
The Lancet, 08/31/09
Calverley PMA et al. – Since different subsets of patients exist within the broad spectrum of COPD, targeted specific therapies could improve disease management. This possibility should be explored further in prospective studies.
Related Articles
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects
British Journal of Clinical Pharmacology, 10/23/09
Relevance Score: 91%
Today in COPD...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages
European Respiratory Journal , 11/25/09
Defective macrophage phagocytosis of bacteria in COPD
European Respiratory Journal , 11/24/09
Alterations in Lung Mast Cell Populations in Patients with COPD
American Journal of Respiratory and Critical Care Medicine, 11/20/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09
Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages
European Respiratory Journal , 11/25/09
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Journal of Allergy and Clinical Immunology, 11/25/09
Sponsor
Article Search
Sponsor